Nemaura Medical (OTCMKTS:NMRD – Get Free Report) is expected to be announcing its resultson Monday, August 10th. Analysts expect the company to post earnings of ($0.08) per share and revenue of $0.20 million for the quarter.
Nemaura Medical Price Performance
Nemaura Medical has a fifty-two week low of $0.00 and a fifty-two week high of $0.05.
Nemaura Medical Company Profile
Nemaura Medical PLC is a medical technology company focused on developing non?invasive monitoring solutions for diabetes management and other metabolic applications. The company’s core offering centers on sugarBEAT, a wearable continuous glucose monitoring (CGM) system designed to provide real-time glucose readings through a disposable skin patch. By eliminating the need for finger-stick testing, Nemaura aims to improve patient comfort and adherence, particularly for individuals managing type 1 and type 2 diabetes.
The sugarBEAT system utilizes a proprietary, mild electric current to extract interstitial fluid through micro-pores in the skin, enabling glucose measurement without needle penetration.
Featured Stories
- Five stocks we like better than Nemaura Medical
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.
